FOUR DAYS BEFORE BONFIRE NIGHT, FIVE LEADING CHARITIES SUPPORTING CHILDREN AND ADULTS WHO HAVE SUSTAINED LIFE CHANGING BURNS WILL JOIN FORCES WITH LONDON FIRE BRIGADE TO CELEBRATE ITS 150TH ANNIVERSARY WITH A CHARITY GALA DINNER AT MANSION HOUSE ON TUESDAY 1 NOVEMBER 2016
News Article | October 29, 2016
With special thanks to Securitas, Canary Wharf Group, Hawkins, Lloyds Charities, B Nokes Contracts, Aico Ltd for their sponsorship of this major City event. The event will benefit five leading charities supporting children and adults who have suffered severe life changing burns, including the medical research charity, Restoration of Appearance and Function Trust (RAFT), who are the event organisers. Throughout 2016 London Fire Brigade (LFB) has been commemorating 150 years of service with a series of activities and events across the capital, culminating in a charity gala dinner at Mansion House on 1 November. The event will be attended by leading organisations, senior decision makers and CEOs from across the private and public sector. Alderman Tim Hailes will be the Lord Mayor’s representative. London Fire Commissioner Ron Dobson CBE,QFSM, FIFireE will be in attendance and Dame Sian Phillips CBE will give the opening speech on the night. The dinner will support five charities for their research and support of children and adults that have suffered severe life changing burns. Every year an estimated 265,000 deaths are caused by burns globally. In the UK, nearly 8,000 people are admitted to A&E with burns related injuries. The five benefiting charities are the Restoration of Appearance and Function Trust (RAFT), Children’s Burns Trust, Burns Camps, The Firefighters Charity, and Children of Fire. Each charity provides support to burns victims in different ways, from the innovative burns research RAFT is conducting to the care given to poor families in Africa and rehabilitation provided to children in the UK. “What better way to conclude a year of 150th celebration than by raising money for such a good cause. The work these charities do with those who have suffered life changing burn injuries is very important and close to many firefighters hearts and that’s why a lot of our 150th community celebrations have been geared towards fundraising for them. “We aim to have raised thousands by the end of the year and this gala dinner will help towards that ambition” Leonor Stjepic, CEO at RAFT commented, “We are very proud of our long relationship with London Fire Brigade and our collaboration with these amazing charities that are dedicated to improving the lives of people who have suffered life changing injuries. I’m delighted we have gained the support of so many leading companies such as Securitas and Canary Wharf Group. Their support will make a significant contribution to the success of the evening” For more information about London Fire Brigade and the 150 th anniversary plans please visit: www.LFB150.co.uk Firefighters Charity www.firefighterscharity.org.uk The Fire Fighters Charity is the UK’s leading provider of life enhancing health and wellbeing services to the fire community. Founded during the second world war to support the families of firefighters killed during the Blitz, the Charity today covers the whole of the UK, supporting beneficiaries in their recovery from illness or injury, or equipping them with the tools they need to manage their conditions and enhance their quality of life Restoration of Appearance and Function Trust (RAFT) is a medical research charity established in 1988 to develop better healing techniques for burns victims, so patients recovered faster with less scarring. Today the charity’s aim is to give people who have suffered severe tissue damage caused by accidents, disease or birth abnormality access to pioneering new treatments that will significantly improve their quality of life, independence and dignity. Children’s Burns Trust www.cbtrust.org.uk Children’s Burns Trust is the only UK children’s charity working nationally to prevent burns and scalds happening to children, raise awareness of good first aid, provide rehabilitation and direct support to burn injured children and their families. Burns Camp www.burncamps.org.uk The Burn Camps Charity is there to help raise the self esteem and confidence of young burns survivors through challenging but achievable goals. Be it at residential camps or day activities. Sharing their experiences with other burns survivors and making many life long friends along the way. Children of Fire www.childrenoffire.org Children of Fire was established in 1996 and is focussed on providing support to children that have been severely burned in villages and townships in South Africa and other parts of Africa where medical facilities and ongoing support is extremely limited. Education plays a big role in preventing accidents and the charity is raising money to focus on this important area. For press information please contact: John Abbey [email protected] on 0208 433 6793 or mobile 07730 65 8888
News Article | November 30, 2016
Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Fibrinogen Concentrate is used as a medicine for blood disease. Fibrinogen concentrate is a preparation of coagulation factors prepared from pooled plasma. Also known as “fibrin glue” or “fibrin sealant”, the majority of available formulations contain a mixture of pooled plasma-derived fibrinogen and the enzyme thrombin. Scope of the Report: This report focuses on the Fibrinogen Concentrate in Global Market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Market Segment by Manufacturers, this report covers CSL Behring Baxter Johnson & Johnson (Ethicon) LFB Group ProFibrix BV (The Medicines Company) Shanghai RAAS Jiangxi Boya Bio-Pharmaceutical Hualan Biological Engineering Harbin Pacific Biopharmaceutical Greencross Shanghai XinXing Medical Market Segment by Regions, regional analysis covers North America (USA, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America, Middle East and Africa Market Segment by Applications, can be divided into Congenital Fibrinogen Deficiency Surgical Procedures (Trauma Patients, Cardiovascular Surgery Patients, PPH Patients, Plastic Surgery Patients) Global Fibrinogen Concentrate Market by Manufacturers, Regions, Type and Application, Forecast to 2021 1 Market Overview 1.1 Fibrinogen Concentrate Introduction 1.2 Market Analysis by Type 1.2.1 Human Fibrinogen Concentrate 1.2.2 Animal?Fibrinogen Concentrate 1.2.3 1.3 Market Analysis by Applications 1.3.1 Congenital Fibrinogen Deficiency 1.3.2 Surgical Procedures (Trauma Patients, Cardiovascular Surgery Patients, PPH Patients, Plastic Surgery Patients) 1.3.3 1.4 Market Analysis by Regions 1.4.1 North America (USA, Canada and Mexico) 18.104.22.168 USA 22.214.171.124 Canada 126.96.36.199 Mexico 1.4.2 Europe (Germany, France, UK, Russia and Italy) 188.8.131.52 Germany 184.108.40.206 France 220.127.116.11 UK 18.104.22.168 Russia 22.214.171.124 Italy 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) 126.96.36.199 China 188.8.131.52 Japan 184.108.40.206 Korea 220.127.116.11 India 18.104.22.168 Southeast Asia 1.4.4 South America, Middle East and Africa 22.214.171.124 Brazil 126.96.36.199 Egypt 188.8.131.52 Saudi Arabia 184.108.40.206 South Africa 220.127.116.11 Nigeria 1.5 Market Dynamics 1.5.1 Market Opportunities 1.5.2 Market Risk 1.5.3 Market Driving Force 2 Manufacturers Profiles 2.1 CSL Behring 2.1.1 Business Overview 2.1.2 Fibrinogen Concentrate Type and Applications 18.104.22.168 Type 1 22.214.171.124 Type 2 2.1.3 CSL Behring Fibrinogen Concentrate Sales, Price, Revenue, Gross Margin and Market Share 2.2 Baxter 2.2.1 Business Overview 2.2.2 Fibrinogen Concentrate Type and Applications 126.96.36.199 Type 1 188.8.131.52 Type 2 2.2.3 Baxter Fibrinogen Concentrate Sales, Price, Revenue, Gross Margin and Market Share 2.3 Johnson & Johnson (Ethicon) 2.3.1 Business Overview 2.3.2 Fibrinogen Concentrate Type and Applications 184.108.40.206 Type 1 220.127.116.11 Type 2 2.3.3 Johnson & Johnson (Ethicon) Fibrinogen Concentrate Sales, Price, Revenue, Gross Margin and Market Share 2.4 LFB Group 2.4.1 Business Overview 2.4.2 Fibrinogen Concentrate Type and Applications 18.104.22.168 Type 1 22.214.171.124 Type 2 2.4.3 LFB Group Fibrinogen Concentrate Sales, Price, Revenue, Gross Margin and Market Share 2.5 ProFibrix BV (The Medicines Company) 2.5.1 Business Overview 2.5.2 Fibrinogen Concentrate Type and Applications 126.96.36.199 Type 1 188.8.131.52 Type 2 2.5.3 ProFibrix BV (The Medicines Company) Fibrinogen Concentrate Sales, Price, Revenue, Gross Margin and Market Share 2.6 Shanghai RAAS 2.6.1 Business Overview 2.6.2 Fibrinogen Concentrate Type and Applications 184.108.40.206 Type 1 220.127.116.11 Type 2 2.6.3 Shanghai RAAS Fibrinogen Concentrate Sales, Price, Revenue, Gross Margin and Market Share 2.7 Jiangxi Boya Bio-Pharmaceutical 2.7.1 Business Overview 2.7.2 Fibrinogen Concentrate Type and Applications 18.104.22.168 Type 1 22.214.171.124 Type 2 2.7.3 Jiangxi Boya Bio-Pharmaceutical Fibrinogen Concentrate Sales, Price, Revenue, Gross Margin and Market Share 2.8 Hualan Biological Engineering 2.8.1 Business Overview 2.8.2 Fibrinogen Concentrate Type and Applications 126.96.36.199 Type 1 188.8.131.52 Type 2 2.8.3 Hualan Biological Engineering Fibrinogen Concentrate Sales, Price, Revenue, Gross Margin and Market Share 2.9 Harbin Pacific Biopharmaceutical 2.9.1 Business Overview 2.9.2 Fibrinogen Concentrate Type and Applications 184.108.40.206 Type 1 220.127.116.11 Type 2 2.9.3 Harbin Pacific Biopharmaceutical Fibrinogen Concentrate Sales, Price, Revenue, Gross Margin and Market Share 2.10 Greencross 2.10.1 Business Overview 2.10.2 Fibrinogen Concentrate Type and Applications 18.104.22.168 Type 1 22.214.171.124 Type 2 2.10.3 Greencross Fibrinogen Concentrate Sales, Price, Revenue, Gross Margin and Market Share 2.11 Shanghai XinXing Medical 2.11.1 Business Overview 2.11.2 Fibrinogen Concentrate Type and Applications 126.96.36.199 Type 1 188.8.131.52 Type 2 2.11.3 Shanghai XinXing Medical Fibrinogen Concentrate Sales, Price, Revenue, Gross Margin and Market Share 3 Global Fibrinogen Concentrate Market Competition, by Manufacturer 3.1 Global Fibrinogen Concentrate Sales and Market Share by Manufacturer 3.2 Global Fibrinogen Concentrate Revenue and Market Share by Manufacturer 3.3 Market Concentration Rate 3.3.1 Top 3 Fibrinogen Concentrate Manufacturer Market Share 3.3.2 Top 6 Fibrinogen Concentrate Manufacturer Market Share 3.4 Market Competition Trend 4 Global Fibrinogen Concentrate Market Analysis by Regions 4.1 Global Fibrinogen Concentrate Sales, Revenue and Market Share by Regions 4.1.1 Global Fibrinogen Concentrate Sales by Regions (2011-2016) 4.1.2 Global Fibrinogen Concentrate Revenue by Regions (2011-2016) 4.2 North America Fibrinogen Concentrate Sales and Growth (2011-2016) 4.3 Europe Fibrinogen Concentrate Sales and Growth (2011-2016) 4.4 Asia-Pacific Fibrinogen Concentrate Sales and Growth (2011-2016) 4.5 South America Fibrinogen Concentrate Sales and Growth (2011-2016) 4.6 Middle East and Africa Fibrinogen Concentrate Sales and Growth (2011-2016) Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
News Article | December 10, 2016
— Chronic Lymphocytic Leukemia (CLL) Pipeline Market Companies Involved in Therapeutics Development are 4SC AG, AbbVie Inc, Acetylon Pharmaceuticals Inc, Aeglea BioTherapeutics Inc, Altor BioScience Corp, Amgen Inc, Aprea AB, Aptevo Therapeutics Inc, Arno Therapeutics Inc, ArQule Inc, Astellas Pharma Inc, Astex Pharmaceuticals Inc, Baliopharm AG, Bayer AG, BeiGene Ltd, Bellicum Pharmaceuticals Inc, Biogen Inc, Bionomics Ltd, Bionovis SA, Biothera Pharmaceutical Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corp, Cellectis SA, Cellular Biomedicine Group Inc, Coherus BioSciences Inc, CrystalGenomics Inc, Cyclacel Pharmaceuticals Inc, Daiichi Sankyo Company Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GeneaMed Ltd, Genentech Inc, Genor BioPharma Co Ltd, Gilead Sciences Inc, Grupo Ferrer Internacional SA, Hutchison MediPharma Ltd, Hybrigenics SA, Igenica Biotherapeutics Inc, Immatics Biotechnologies GmbH, ImmunoGen Inc, Immunomedics Inc, Incyte Corp, Inflection Biosciences Ltd, Innate Pharma SA, Innovent Biologics Inc, Johnson & Johnson, Juno Therapeutics Inc, Kancera AB, Karyopharm Therapeutics Inc, Kite Pharma Inc, Les Laboratoires Servier SAS, LFB SA, Lymphocyte Activation Technologies SA, Medicenna Therapeutics Inc, MENTRIK Biotech LLC, Merck & Co Inc, Merck KGaA, Mesoblast Ltd, Millennium Pharmaceuticals Inc, MorphoSys AG, NantKwest Inc, Nordic Nanovector ASA, Novartis AG, Oncternal Therapeutics, Inc., Ono Pharmaceutical Co Ltd, Panacea Biotec Ltd, PEP-Therapy SAS, Pfizer Inc, Pharmacyclics Inc, PIQUR Therapeutics AG, Portola Pharmaceuticals Inc, Redx Pharma Plc, Respiratorius AB, Revitope Oncology, Inc., Rhizen Pharmaceuticals SA, Sandoz International GmbH, Sanofi, Selvita SA, Simcere Pharmaceutical Group, Sorrento Therapeutics Inc, Supratek Pharma Inc, Takeda Pharmaceutical Company Ltd, Targazyme Inc, TG Therapeutics Inc, The International Biotechnology Center (IBC) Generium, Theravectys SA, Tolero Pharmaceuticals Inc, TRACON Pharmaceuticals Inc, Tragara Pharmaceuticals Inc, Trillium Therapeutics Inc, United BioPharma, Inc., Unum Therapeutics Inc, Verastem Inc, VioQuest Pharmaceuticals Inc, Viralytics Ltd, Xencor Inc, ZIOPHARM Oncology Inc and Zymeworks Inc. This research provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Inquire more about this research report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=774108 The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 5, 43, 45, 1, 3, 54, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 6, 8 and 7 molecules, respectively. Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Buy a copy of this research report at http://www.reportsnreports.com/purchase.aspx?name=774108 • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology). • The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/774108-chronic-lymphocytic-leukemia-cll-pipeline-review-h2-2016.html
PubMed | ECDYSIS Pharma, VU University Amsterdam, University Paris - Sud, CNRS Galen Institute and LFB
Type: | Journal: Analytica chimica acta | Year: 2016
Antithrombin (AT) is a plasma glycoprotein which possesses anticoagulant and anti-inflammatory properties. AT exhibits various forms, among which are native, latent and heterodimeric ones. We studied the potential of capillary electrophoresis-mass spectrometry (CE-MS) using a sheath liquid interface, electrospray ionization (ESI), and a quadrupole-time-of-flight (Q-TOF) mass spectrometer to separate and quantify the different AT forms. For CE separation, a neutral polyvinyl alcohol (PVA) coated capillary was employed. The protein conformation was preserved by using a background electrolyte (BGE) at physiological pH. A sheath liquid of isopropanol-water 50:50 (v/v) with 14mM ammonium acetate delivered at a flow rate of 120Lh
News Article | December 20, 2016
BERNAY, France--(BUSINESS WIRE)--Lors de la cérémonie de remise des Awards de Connect + Event qui s'est tenue le jeudi 8 Décembre 2016 à Villepinte dans le cadre du salon Smart Industries, la société Biolog-id a été gratifiée de l’award « Meilleure solution Objets connectés industriels » pour sa solution complète de traçabilité des poches de sang. Biolog-id a développé une solution totalement intégrée, du donneur au patient, qui garantit l’identification, la traçabilité et une gestion optimisée des poches de sang, dans un univers en permanence connecté avec les logiciels médico-techniques des Etablissements de transfusion et/ou de soins. Ces poches connectées garantissent la sécurité de l’acte transfusionnel en assurant la délivrance de la bonne poche de sang au bon patient. Les poches sont identifiées et tracées grâce à un tag RFID ; des enceintes réfrigérées intelligentes permettent le stockage dans des conditions optimales ainsi que la connaissance des stocks et des mouvements en temps réel. L’ensemble est piloté par une solution informatique dédiée qui s’interface avec la majorité des systèmes d’exploitation existants. Connect+ Event est le salon dédié aux Objet Connectés Professionnels et partie prenante de l’événement fédérateur « Convergence pour l’Industrie du Futur » qui rassemble MIDEST, Smart Industries et le Forum Convergence. Ce salon, voulu et inauguré par le Président de la République François Hollande, s’inscrit dans une dimension internationale. À propos de Biolog-id Biolog-id est une société française qui conçoit, développe et commercialise des solutions de gestion et de traçabilité pour les produits de santé, notamment les produits sanguins labiles (concentré de globules rouges, plaquettes, plasma thérapeutique), le plasma pour fractionnement destiné à la fabrication de médicaments dérivés du sang et les préparations injectables de chimiothérapies. En 2015, le groupe LFB, la société Biolog-id et l'Etablissement Français du Sang (EFS) ont annoncé la mise en place du système de traçabilité par RFID développé par Biolog-id sur l'ensemble des poches de plasma. L'expertise approfondie de la société en matière de traçabilité par RFID lui permet d’être positionnée comme la référence mondiale pour la traçabilité des produits de santé sensibles. http://www.biolog-id.com Biolog-id est soutenue par Xerys Gestion, société de gestion de portefeuille spécialisée dans le capital-investissement et agréée par l’Autorité des Marchés Financiers.
News Article | November 16, 2016
— Factors such as rising geriatric population and increasing number of hemophilic patients are boosting the market growth. However, strict government rules, huge cost and limited reimbursements are some of the factors hampering the market. Rising digit of Hemophilic Patients is creating growth opportunities for vendors in the market. By product, immunoglobulin segment dominated the global market with largest share in 2013 owing to growing geriatric population with neurological and autoimmune disease. By region, North America accounted for largest market share followed by Europe. However, Asia-Pacific is anticipated to grow at the highest CAGR owing to increasing digit of hemophilic patients and rising awareness of technologically advanced products in this region. Some of the key players in Plasma Fractionation market include Octapharma AG, Chinese Biological Products, Inc., Baxter International, Inc., Bio Products Laboratory, Grifols International SA, Shanghai Raas Blood Products Co., Ltd, Csl, Ltd., China Biologic Products, Inc., Kedrion S.P.A., Biotest, Sanquin and LFB SA. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com/
News Article | November 29, 2016
The report provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016 addition with 51 market data tables and 14 figures, spread across 266 pages is available at http://www.reportsnreports.com/reports/764550-refractory-chronic-lymphocytic-leukemia-cll-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, Investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis AbbVie Inc, Arno Therapeutics,Astellas Pharma Inc.,Astex Pharmaceuticals Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Cellular Biomedicine Group, F. Hoffmann-La Roche Ltd., Gilead Sciences, Hutchison MediPharma Limited, ImmunoGen, Immunomedics, Incyte Corporation, Innate Pharma S.A., Juno Therapeutics Inc., Karyopharm Therapeutics, LFB S.A., Lymphocyte Activation Technologies, Medicenna Therapeutics, Inc., Millennium Pharmaceuticals Inc, MorphoSys AG, Novartis AG, Oncternal Therapeutics, Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=764550 premium report price at US$2000 for a single user PDF license).
News Article | November 16, 2016
Leukocyte concentration, red cell concentration, plasma for transfusion, and platelet concentration, are some of the blood products, which are obtained from the processing of single donations of blood or plasma. In whole blood, red blood cells, leukocytes, and platelets are suspended within the plasma. Blood plasma is the liquid component of the whole blood, and makes up approximately 55% of the total blood volume. It is a complex biological material mainly composed of water with small amount of minerals, ions, nutrients, salts, and proteins in the solution. Human plasma is composed of protease inhibitors, protease, fibrinolytic proteins, coagulation factors, and anti-coagulant proteins. Human plasma is obtained through large scale processing steps known as fractionation, i.e. a sequence of process in which plasma is separated for medicinal use. Human blood plasma is obtained by separating the plasma from the whole blood or by apheresis. Differential solubility of proteins, differential interaction of protein with solid media and interaction with physical field are various methods for plasma fraction. Human plasma for fractionation is the starting material for the manufacture of a range of medicinal products used for the treatment of a variety of life-threatening injuries and diseases such as immunological disorders, infections, trauma, and congenital deficiencies. In addition, with extensive measures to eliminate infectious donations along with various steps to eliminate and inactivate contaminated virus has reduced the risk of disease transmission by plasma products. Technological innovation and production methods of plasma fractionation are helping to extensively improve product purity, and the yields of plasma-derived proteins in plasma fractionation. North America dominates the global market for plasma fraction due to rise in neurological and autoimmune disorders, and increasing geriatric population in the region. Asia is expected to show high growth rates in the next five years in the global plasma fraction market, with China and India being the fastest-growing markets in the Asia Pacific region. The key driving forces for the plasma fraction market in developing countries are the large pool of patients, increasing awareness about the disease, increasing disposable income, rising number of hemophilic patients, increasing organ transplantation, increasing use of immunoglobulins, and rising government funding in the region. Increasing number of hemophilic patients, rise in geriatric population, increase in healthcare awareness and expenditure, growing off-label use of albumin and immunoglobulin in various chronic diseases, increased diagnosis rate of diseases, rise in the use of prophylactic treatment for bleeding and immune diseases, and increasing disposable income in developing countries are some of the key factors driving the growth of the global plasma fraction market. However, strict government regulations, high cost and limited reimbursement, economic slowdown, and rising number of recombinant products act as major restraints for the growth of the global plasma fraction market. Request TOC (desk of content material), Figures and Tables of the report: http://www.persistencemarketresearch.com/toc/4258 Some of the major trends in the global plasma fraction market are increasing market consolidation, rising adoption of subcutaneous Ig ScIg therapy, increasing number of local players, and rising number of plasma fraction collection centers. The major companies operating in the global plasma fraction market are Baxter International, Inc., Octapharma AG, Biotest AG, CSL, Ltd., Grifols International S.A., Kedrion S.p.A., LFB S.A., Chinese Biological Products, Inc., and Shanghai RAAS Blood Products Co., Ltd.
News Article | November 10, 2016
MINNEAPOLIS--(BUSINESS WIRE)--#DQSA--Verify Brand is pleased to announce the recent achievement by its client, LFB USA, Inc., of a significant milestone in efforts to meet the November 2017 requirements of the U.S. Drug Supply Chain and Security Act (DSCSA). LFB USA has successfully validated its dedicated instance of Verify Brand’s cloud-based platform, the Verify Platform, which included installation, testing, protocol execution and documentation approvals. “One of LFB USA’s main deciding factors in
News Article | December 20, 2016
BERNAY, France--(BUSINESS WIRE)--Biolog-id received the “Best Solution for Industrial Smart Objects” award for its complete blood bag traceability solution during the Connect+ Event awards ceremony on Thursday, December 8, 2016, part of the Smart Industries show in Paris. Biolog-id has developed a fully integrated system that guarantees blood bags can be efficiently identified, tracked and managed from donor to patient within a system that is always connected using medical software at transfusion and/or treatment centers. These smart bags guarantee transfusions are safe by ensuring the right blood bag is delivered to the right patient. Bags are identified and traced using RFID tags. Smart cold storage facilities store blood in optimal conditions and make it easy to track stock levels and movements in real time. The entire system is controlled by a dedicated IT solution that is compatible with the majority of existing operating systems. Biolog-id President Pierre Parent says, “This award is an excellent reward for the teams who worked on this product. They’re seeing the quality and relevance of their work recognized by the main players who are impacted by the major changes the industrial sector is experiencing.” Connect+ Event is a show focused on Professional Smart Objects and a stakeholder in the “Convergence for the Industry of the Future” event, which brings together MIDEST, Smart Industries and the Convergence Forum. This show was encouraged and inaugurated by French President François Hollande and has an international reach. About Biolog-id Biolog-id is a French company that designs, develops, and markets management and traceability solutions for health products, in particular labile blood components (red blood cell concentrate, platelets and therapeutic plasma), plasma for fractionation for manufacturing blood-derived drugs and injectable chemotherapy products. In 2015, the LFB Group, Biolog-id and the Etablissement Français du Sang announced the introduction of an RFID traceability system developed by Biolog-id for all bags containing plasma. The company’s in-depth knowledge of RFID traceability has led to its position as the worldwide leader in sensitive health product traceability. http://www.biolog-id.com Biolog-id is supported by Xerys Gestion, a portfolio management company accredited by the French financial markets authority (A.M.F.), specializing in private equity.